TREATMENT AGENT FOR LUNG CANCER PATIENT, AND METHOD FOR PREDICTING AND TESTING EFFICACY OF TREATMENT FOR LUNG CANCER PATIENT

摘要

Provided is a lung cancer treatment agent for treating lung cancer patients, and particularly EGFR-TKI-resistant NSCLC patients. Also provided is a method for predicting and testing the efficacy of a treatment for lung cancer patients. As a result of painstaking research regarding a treatment agent for lung cancer patients that contains an optimal combination of an HDAC inhibitor and EGFR-TKI, the present invention was perfected based on the discovery that "when the BIM in a sample derived from a EGFR-TKI-resistant NSCLC patient is non-wild, treatment by administering EGFR-TKI alone is minimally effective, whereas treatment involving administrating a treatment agent for lung cancer patients containing JNJ-26481585 and EGFR-TKI in combination, or a treatment agent for lung cancer patients containing CUDC-101 and EGFR-TKI in combination is very effective."